Acumen Pharmaceuticals, Inc.
ABOS · XNASCIK 1576885fmd_0ZQ55BXPP56D66FX9Y52TRDWGKManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 8 | 12 | 32 | 42 | 94 | 105 |
| Total operating expenses | 9 | 20 | 45 | 61 | 114 | 124 |
| Operating income | (8) | (20) | (45) | (61) | (114) | (124) |
| Interest expense | – | – | 0 | 1 | 4 | 4 |
| Interest and investment income | – | – | – | 11 | 14 | 7 |
| Other non-operating income (expense) | 1 | (81) | 2 | 9 | 12 | 2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (7) | (101) | (43) | (52) | (102) | (121) |